Fidia Pharma USA Inc
Amy Bergknopf is an experienced Senior Executive Specialty Sales Representative at Fidia Pharma USA Inc, where responsibilities include selling Hymovis®, Hyalgan®, and Triluron for osteoarthritis treatment since July 2014. Prior to this role, Amy served as a Sales Specialist at PDI, Inc. from January 2010 to June 2014 and as a Senior Neurology Sales Specialist at Teva Pharmaceuticals from 2003 to 2009, where success in exceeding market share goals was achieved by promoting injectable drugs for Multiple Sclerosis. Amy holds a Bachelor of Business Administration in Accounting from Hofstra University.
This person is not in any offices
Fidia Pharma USA Inc
Fidia Pharma USA Inc is a wholly-owned subsidiary of the Italian pharmaceutical manufacturer Fidia Farmaceutici S.p.A., an established leader in the hyaluronic acid (HA) market segment. Fidia Pharma USA is focused on continually expanding Fidia’s position in the U.S. and Canadian market, while upholding the company's mission to provide consumers with innovative products that offer quality, safety and performance, establishing a sound strategic presence of Fidia in the US consistently with the Company's mission and strategy pillars. Drawing on the strengths of the parent company, Fidia Pharma USA product portfolio focuses primarily on therapeutic areas such as joint healthcare and tissue repair. Fidia Pharma USA Inc is headquartered in Parsippany, NJ.